Adocia prepares for Phase III of diabetic foot ulcer treatment
This article was originally published in Scrip
Executive Summary
French biotechnology company Adocia has said it is actively preparing for Phase III trials of its diabetic foot ulcer treatment, BioChaperone combined with PDGF-BB (platelet-derived growth factor BB), for the second half of 2013 in the US and Europe. Simultaneously, it is planning to begin a Phase III trial in India in the fourth quarter of 2012, with a view to registering the drug in emerging countries in late 2014.